EE200100104A - 5-HT4 agonisti või antagonisti uus peroraalne ravimvorm - Google Patents

5-HT4 agonisti või antagonisti uus peroraalne ravimvorm

Info

Publication number
EE200100104A
EE200100104A EEP200100104A EEP200100104A EE200100104A EE 200100104 A EE200100104 A EE 200100104A EE P200100104 A EEP200100104 A EE P200100104A EE P200100104 A EEP200100104 A EE P200100104A EE 200100104 A EE200100104 A EE 200100104A
Authority
EE
Estonia
Prior art keywords
agonist
antagonist
dosage form
oral dosage
novel oral
Prior art date
Application number
EEP200100104A
Other languages
English (en)
Inventor
De Bruijn Karel
Engel G�nter
Pfannkuche Hans-J�rgen
Thewissen Michael
Vitzling Christian
Z�ger Othmar
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200100104(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9818340.3A external-priority patent/GB9818340D0/en
Priority claimed from GBGB9823477.6A external-priority patent/GB9823477D0/en
Priority claimed from GBGB9910320.2A external-priority patent/GB9910320D0/en
Priority claimed from GBGB9911059.5A external-priority patent/GB9911059D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of EE200100104A publication Critical patent/EE200100104A/et
Publication of EE05054B1 publication Critical patent/EE05054B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
EEP200100104A 1998-08-21 1999-08-19 5-HT4 agonisti v?i antagonisti peroraalne ravimkoostis ja selle kasutamine meditsiinis EE05054B1 (et)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9818340.3A GB9818340D0 (en) 1998-08-21 1998-08-21 Organic compounds
GBGB9823477.6A GB9823477D0 (en) 1998-10-27 1998-10-27 Organic compounds
GBGB9910320.2A GB9910320D0 (en) 1999-05-05 1999-05-05 Organic compounds
GBGB9911059.5A GB9911059D0 (en) 1999-05-12 1999-05-12 Organic compounds
PCT/EP1999/006083 WO2000010526A2 (en) 1998-08-21 1999-08-19 New oral formulation for 5-ht4 agonists or antagonists

Publications (2)

Publication Number Publication Date
EE200100104A true EE200100104A (et) 2002-06-17
EE05054B1 EE05054B1 (et) 2008-08-15

Family

ID=27451823

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100104A EE05054B1 (et) 1998-08-21 1999-08-19 5-HT4 agonisti v?i antagonisti peroraalne ravimkoostis ja selle kasutamine meditsiinis

Country Status (29)

Country Link
US (4) US20030236183A1 (et)
EP (1) EP1104289B1 (et)
JP (1) JP4048024B2 (et)
KR (1) KR100529659B1 (et)
CN (2) CN1165293C (et)
AT (1) ATE316782T1 (et)
AU (4) AU762829B2 (et)
BG (1) BG65322B1 (et)
BR (1) BR9913135A (et)
CA (1) CA2338794C (et)
CZ (1) CZ300647B6 (et)
DE (1) DE69929703T2 (et)
DK (1) DK1104289T3 (et)
EE (1) EE05054B1 (et)
ES (1) ES2257869T3 (et)
FR (3) FR2782454B1 (et)
HR (1) HRP20010123B1 (et)
HU (1) HU228179B1 (et)
ID (1) ID28510A (et)
IL (1) IL141236A0 (et)
IS (1) IS2369B (et)
IT (1) IT1314185B1 (et)
NO (1) NO328756B1 (et)
NZ (1) NZ509832A (et)
PL (2) PL200132B1 (et)
RS (1) RS50104B (et)
SK (1) SK285255B6 (et)
TR (3) TR200400187T2 (et)
WO (1) WO2000010526A2 (et)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001270304A1 (en) 2000-07-07 2002-01-21 The Administrators Of The Tulane Educational Fund Methods for protection of stratified squamous epithelium against injury by noxious substances and novel agents for use therefor
AU2002231627A1 (en) * 2000-11-24 2002-06-03 Janssen Pharmaceutica N.V. Use of a triple combination comprising a 5HT3 antagonist, a 5HT4 agonist and a laxative for promoting intestinal lavage
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
AU2004216298B2 (en) * 2003-02-28 2009-04-23 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
WO2004085393A1 (en) * 2003-03-25 2004-10-07 Hetero Drugs Limited Novel crystalline forms of tegaserod maleate
GB0307440D0 (en) * 2003-03-31 2003-05-07 Novartis Ag Organic compounds
PE20050253A1 (es) * 2003-07-24 2005-06-03 Novartis Ag Modificaciones estables de maleato de hidrogeno de tegaserod
US8591968B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Edible composition including a delivery system for active components
US8597703B2 (en) 2005-05-23 2013-12-03 Kraft Foods Global Brands Llc Delivery system for active components as part of an edible composition including a ratio of encapsulating material and active component
US8389032B2 (en) 2005-05-23 2013-03-05 Kraft Foods Global Brands Llc Delivery system for active components as part of an edible composition having selected particle size
US8591973B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Delivery system for active components and a material having preselected hydrophobicity as part of an edible composition
US20050112236A1 (en) 2003-11-21 2005-05-26 Navroz Boghani Delivery system for active components as part of an edible composition having preselected tensile strength
US8591972B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Delivery system for coated active components as part of an edible composition
US8591974B2 (en) 2003-11-21 2013-11-26 Kraft Foods Global Brands Llc Delivery system for two or more active components as part of an edible composition
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
EP3263117A1 (en) 2005-11-28 2018-01-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
WO2011053251A1 (en) 2009-10-30 2011-05-05 Ix Biopharma Pte Ltd Fast dissolving solid dosage form
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
US20140296831A1 (en) 2011-08-20 2014-10-02 Fred Göbel Trans-anal inflow catheter and method for intermittently triggering a reflex-coordinated defecation
UA118339C2 (uk) * 2012-09-03 2019-01-10 Біогайа Аб Бактеріальний штам lactobacillus gasseri для лікування порушення моторики кишечнику (варіанти)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US552398A (en) * 1895-12-31 Riveting-machine
JP2708803B2 (ja) * 1987-09-02 1998-02-04 中外製薬株式会社 持続放出製剤
DK0472502T3 (da) * 1990-08-24 1995-10-09 Spirig Ag Fremgangsmåde til fremstilling af pellets
HUT64023A (en) * 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
US5523289A (en) * 1991-04-15 1996-06-04 Abbott Laboratories Pharmaceutical composition
US20020128172A1 (en) * 1991-12-21 2002-09-12 Smithkline Beecham Plc Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases
FR2710915B1 (fr) * 1993-10-04 1995-11-24 Synthelabo Dérivés de pipéridine, leur préparation et leur utilisation en thérapeutique.
TW270114B (et) * 1993-10-22 1996-02-11 Hoffmann La Roche
US5399562A (en) * 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
JPH0820586A (ja) * 1994-07-05 1996-01-23 Sanwa Kagaku Kenkyusho Co Ltd １−アザビシクロ［３．３．０］オクタン誘導体、その塩及び製法並びに用途
MX9704079A (es) * 1994-12-01 1997-12-31 Cibus Pharmaceutical Inc Liberacion de farmacos antiinflamatorios no esteroides empleando uan goam hidrocoloide en polvo que se obtiene de plantas superiores.
US5654320A (en) * 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
FR2753196B1 (fr) * 1996-09-12 1998-10-23 Synthelabo Derives d'indazole tricyclique, leur preparation et leur application en therapeutique
JP2001526212A (ja) * 1997-12-19 2001-12-18 スミスクライン・ビーチャム・コーポレイション 咀嚼分散性錠剤の製造法
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod

Also Published As

Publication number Publication date
JP2002523351A (ja) 2002-07-30
NO20010863D0 (no) 2001-02-20
IS2369B (is) 2008-06-15
DE69929703T2 (de) 2007-02-22
HRP20010123B1 (hr) 2010-11-30
RS50104B (sr) 2009-01-22
PL346764A1 (en) 2002-02-25
EE05054B1 (et) 2008-08-15
IT1314185B1 (it) 2002-12-06
US20080075773A1 (en) 2008-03-27
FR2782454B1 (fr) 2005-12-02
TR200100361T2 (tr) 2001-06-21
ES2257869T3 (es) 2006-08-01
BR9913135A (pt) 2001-05-08
EP1104289A2 (en) 2001-06-06
AU2006200048A1 (en) 2006-02-02
CA2338794A1 (en) 2000-03-02
PL194069B1 (pl) 2007-04-30
ITMI991826A1 (it) 2001-02-19
CA2338794C (en) 2009-01-20
WO2000010526A3 (en) 2000-09-08
HUP0103431A2 (hu) 2002-01-28
HRP20010123A2 (en) 2002-02-28
US20030236183A1 (en) 2003-12-25
FR2784899B1 (fr) 2001-08-17
FR2782454A1 (fr) 2000-02-25
NZ509832A (en) 2003-11-28
HK1038179A1 (en) 2002-03-08
HUP0103431A3 (en) 2002-02-28
KR20010079668A (ko) 2001-08-22
WO2000010526A2 (en) 2000-03-02
DK1104289T3 (da) 2006-05-15
FR2784899A1 (fr) 2000-04-28
TR200400187T2 (tr) 2006-11-21
PL200132B1 (pl) 2008-12-31
AU2009200403A1 (en) 2009-02-26
IL141236A0 (en) 2002-03-10
NO20010863L (no) 2001-03-26
FR2799123B1 (fr) 2005-12-02
ID28510A (id) 2001-05-31
YU8701A (sh) 2003-12-31
CN1589906A (zh) 2005-03-09
AU2003248212A1 (en) 2003-10-30
CZ300647B6 (cs) 2009-07-08
DE69929703D1 (de) 2006-04-13
AU762829B2 (en) 2003-07-03
ITMI991826A0 (it) 1999-08-19
BG65322B1 (bg) 2008-02-29
AU5623299A (en) 2000-03-14
TR200102259T2 (tr) 2002-06-21
SK285255B6 (sk) 2006-09-07
KR100529659B1 (ko) 2005-11-21
HU228179B1 (en) 2013-01-28
FR2799123A1 (fr) 2001-04-06
JP4048024B2 (ja) 2008-02-13
NO328756B1 (no) 2010-05-03
US20120071537A1 (en) 2012-03-22
CZ2001619A3 (en) 2001-05-16
IS5851A (is) 2001-01-20
EP1104289B1 (en) 2006-02-01
SK2432001A3 (en) 2001-09-11
US20130158092A1 (en) 2013-06-20
CN1323200A (zh) 2001-11-21
BG105257A (en) 2001-11-30
CN1165293C (zh) 2004-09-08
ATE316782T1 (de) 2006-02-15

Similar Documents

Publication Publication Date Title
EE05054B1 (et) 5-HT4 agonisti v?i antagonisti peroraalne ravimkoostis ja selle kasutamine meditsiinis
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
CY1111698T1 (el) Συνδυασμος που περιλαμβανει εναν ανταγωνιστη υποδοχεα ατ1 και εναν ενισχυτη εκκρισης ινσουλινης ή εναν ευαισθητοποιητη ινσουλινης
HRP20020158B1 (en) Action of synergistic combination
BR9810495A (pt) Composição farmacêutica
DE69922676D1 (de) N-aralkylaminotetraline als neuropeptid-y-y5-rezeptorliganden
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
ATE541562T1 (de) Ibuprofen-suspension
SE0102843D0 (sv) Stabilized oral pharmaceutical composition containing lodide and lodate and method
MXPA03010054A (es) Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.
DE69819539D1 (de) Antithrombotische mittel
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose
HRP20050342B1 (hr) Farmaceutska formulacija olanzapina
MXPA01011842A (es) Composiciones farmaceuticas para la administracion oral de floroglucinol y preparacion de las mismas.
YU87501A (sh) Farmaceutski kompleksi
DE69828522D1 (de) Antithrombotische mittel
TR200003451T2 (tr) Pirimidin-Aminometil-Piridin Türevleri, Hazırlanmaları ve helikobakter bakterinin kontrolünde kullanımları
ATE299027T1 (de) Verwendung von übersulfatierten polysacchariden als hiv-hemmer
MY128958A (en) New oral formulation for 5-ht4 agonists or antagonists.
EA200401617A1 (ru) Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера
ECSP993104A (es) Nueva formulacion oral
CR6300A (es) Nueva formulacion oral

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231